Sugars, or glycans, coat every protein in the body and control how the immune system recognizes disease — yet nearly all drugs still target proteins alone. This blind spot leaves major conditions like cancer, fibrosis, and autoimmunity unsolved.

Anomer Bio is developing a new class of immunotherapies that target glycans directly. Its platform combines multi-omics data, Nobel Prize–winning sugar biology, and human trial insights to design synthetic sugars that reprogram immune responses.

Founded by Oxford and Imperial-trained researchers Sophie James and Marcos Burger Ramos, the company’s lead program focuses on triple-negative breast cancer, addressing a ~$13B global market where 50% of patients fail to respond to existing immunotherapies. Beyond this initial indication, Anomer’s technology has even broader potential across immune and fibrotic diseases.